Company Filing History:
Years Active: 2018-2020
Title: The Innovative Contributions of Ryan Dittamore in Cancer Diagnostics
Introduction
Ryan Dittamore is an esteemed inventor based in San Diego, California, known for his significant contributions to the field of cancer diagnostics. With a total of two patents to his name, Dittamore’s innovative work lies particularly in the detection and characterization of circulating tumor cells (CTCs) related to prostate cancer.
Latest Patents
Dittamore's latest patents showcase groundbreaking methodologies for improving prostate cancer diagnostics. One patent focuses on a method for detecting castration-resistant prostate cancer (CRPC) by performing a direct analysis of nucleated cells in blood samples. This process includes immunofluorescent staining and morphological characterization to identify CTCs. The method involves determining the prevalence of a specific CTC subpopulation associated with CRPC, aiding in the diagnosis by comparing the prevalence to a predetermined threshold value.
Additionally, his other patent discusses automated characterization of CTCs, utilizing automated tissue strainers. This innovation allows for simultaneous detection of critical genetic alterations such as ERG rearrangements and PTEN deletions within the same CTC, highlighting a significant advancement in cancer diagnostics. The disclosed methods aim to streamline the characterization process, providing kits designed to facilitate these analyses.
Career Highlights
Dittamore has amassed extensive experience in the biotechnology sector, having contributed significantly to notable companies in the industry. He has worked with Epic Sciences, Inc. and Ventana Medical Systems, Inc., where he has played vital roles in advancing diagnostic technologies.
Collaborations
Throughout his career, Dittamore has collaborated with esteemed colleagues, including Gary A Pestano and Karl Eric Garsha. These partnerships demonstrate the collaborative spirit inherent in the field of scientific innovation, as they work together towards enhancing cancer diagnostic methodologies.
Conclusion
Ryan Dittamore's work in the area of circulating tumor cell diagnostics has set a remarkable precedent in the realm of prostate cancer detection. His innovative approaches not only enhance diagnostic accuracy but also pave the way for future research and development within the field of oncology. With his two patents, Dittamore continues to contribute to critical advancements that may significantly impact patient outcomes in cancer treatment.